Breaking News
November 14, 2018 - Researchers to develop sports-specific classification system for blind football
November 14, 2018 - Preschool children show awake responses to naptime nonsense words
November 14, 2018 - Survey shows negative effect of vulvovaginal atrophy symptoms on quality of life for women
November 14, 2018 - Study sheds light on mechanisms that prevent autoimmune attack
November 14, 2018 - Sleep quality found to be worse for women who undergo surgical menopause
November 14, 2018 - New study provides deeper insight into chromosome segregation during mitosis
November 14, 2018 - Appendix removal is linked to lower risk of Parkinson’s
November 14, 2018 - Lifting weights for less than an hour a week may reduce cardiovascular disease risk
November 14, 2018 - Pulmonary rehabilitation rarely received by hospitalized COPD patients despite health benefits
November 14, 2018 - New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers
November 14, 2018 - Regular head circumference assessment of preterm babies can help identify long-term IQ problems
November 14, 2018 - Brigham investigators examine opioid use among Massachusetts adolescents, prescription trends
November 14, 2018 - Study defines biomarker in response to treatment of castration-resistant prostate cancer
November 14, 2018 - Study identifies potential therapeutic strategy for patients with clear cell renal cancer
November 14, 2018 - Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults
November 14, 2018 - Alpha Fetoprotein (AFP) Tumor Marker Test: MedlinePlus Lab Test Information
November 14, 2018 - Researchers evaluate controversial treatment for Parkinson’s disease psychosis
November 14, 2018 - AI could help veterinarians code their notes
November 14, 2018 - Pre-schoolers with autism thrive in mainstream classroom settings
November 14, 2018 - Individual and work-related factors may help promote hospital physician engagement, finds study
November 14, 2018 - Complementary and alternative medicine is widely used by general population in England
November 14, 2018 - Study reveals link between tobacco availability and smoking during pregnancy
November 14, 2018 - Purdue researchers develop translucent base for silicon patches to deliver exact doses of biomolecules
November 14, 2018 - New technology based on moths and magnets could help treat genetic diseases
November 14, 2018 - Concussion-Related Biomarkers Vary Based on Sex, Race
November 14, 2018 - One more year of high school may shape waistlines later in life
November 14, 2018 - Dissecting high drug costs – Scope
November 14, 2018 - Study shows novel strategy to reduce breast cancer bone metastasis
November 14, 2018 - Empowering the NHS through Industry Partnerships
November 14, 2018 - One size does not fit all in obesity treatment, study finds
November 14, 2018 - Seeking ways to prevent ‘secondary cataracts’
November 14, 2018 - Change Within the Eye May Be Early Warning for Macular Degeneration
November 14, 2018 - Study of 500,000 people clarifies the risks of obesity
November 14, 2018 - Ultrasound releases drug to alter activity in targeted brain areas in rats | News Center
November 14, 2018 - Umass Amherst researchers battle against youth suicide in rural Alaska Native communities
November 14, 2018 - Cancer stem cells depend on amino acid metabolism, and it’s proving to be their Achilles’ heel
November 14, 2018 - Epigenetic link found between prenatal exposure to maternal smoking and offspring’s cardio-metabolic health
November 14, 2018 - Meditation, music may change biomarkers of cellular aging and Alzheimer’s disease in older adults
November 14, 2018 - Multidisciplinaryresearch teams selected to study age-related brain disorders
November 14, 2018 - The Current issue of “The view from here” is concerned with Informatics
November 14, 2018 - Researchers identify tool to help transgender women have a more authentic voice
November 14, 2018 - Four faculty members appointed to endowed professorships | News Center
November 13, 2018 - Research finds strongest evidence yet that obesity causes depression
November 13, 2018 - Researchers compare stools of breastfed and formula-fed infants
November 13, 2018 - Entasis Therapeutics Announces Zoliflodacin Phase 2 Results Published in The New England Journal of Medicine
November 13, 2018 - Gene changes driving myopia reveal new focus for drug development
November 13, 2018 - $6 million grant to support study of preeclampsia, atherosclerosis links | News Center
November 13, 2018 - Beneficial gut microbes metabolize high-fiber diet to improve heart health in mouse model
November 13, 2018 - Excessive use of social media through visual postings linked to increase in narcissistic traits
November 13, 2018 - Study finds why obesity both fuels cancer growth and helps immunotherapy to kill tumors
November 13, 2018 - Women prefer and invest more in daughters, while men favor sons
November 13, 2018 - With hospitalization losing favor, judges order outpatient mental health treatment
November 13, 2018 - Transgenic rat model may provide new insights into cerebral amyloid angiopathy
November 13, 2018 - Study identifies factors tied to greater risk of advanced liver disease in cystic fibrosis patients
November 13, 2018 - Risk of blindness among premature babies with low levels of blood platelets
November 13, 2018 - A new strategy for combatting antibiotic-resistant infections
November 13, 2018 - Study aims to find which outreach method is more effective at improving cancer screening rates
November 13, 2018 - Insufficient sleep duration linked with unhealthy lifestyle profile among children
November 13, 2018 - IIASA researchers introduce new, simple measure for human wellbeing
November 13, 2018 - Magnetic nanosprings used as targeted drug delivery agents for anticancer therapy
November 13, 2018 - Scientists examine FCMs containing silver nanoparticles
November 13, 2018 - Failed DNA repair triggers chromosomal chaos
November 13, 2018 - Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma
November 13, 2018 - Food insecurity during pregnancy linked to severity of neonatal abstinence syndrome
November 13, 2018 - Majority of Americans are concerned about health threat posed by antibiotic resistance
November 13, 2018 - Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma
November 13, 2018 - Study finds women with pregnancy-related nausea, vomiting use marijuana more
November 13, 2018 - Lethal heart rhythm more likely to be found in patients with common heart failure
November 13, 2018 - Study provides new clues to origin and development of multiple sclerosis
November 13, 2018 - Climate change could pose threat to male fertility
November 13, 2018 - Researchers discover how mitochondria deploy a powerful punch against disease-causing bacteria
November 13, 2018 - AHA: Traumatic Childhood Could Increase Heart Disease Risk in Adulthood
November 13, 2018 - Feeling the Burn? | NIH News in Health
November 13, 2018 - Women’s birth canals in Kenya, Korea, Kansas not the same: study
November 13, 2018 - Fecal microbiota transplantation effective against ICI-associated colitis
November 13, 2018 - New physical activity guidelines released that urge people to “move more”
November 13, 2018 - Angiotensin receptor blockers improve sodium excretion in blacks
November 13, 2018 - New project seeks to address alarming injury rate in youth footballers
November 13, 2018 - Fish oil or omega 3 fatty acid supplements can prevent heart attacks finds study
November 13, 2018 - The Human Heart-in-a-Jar That Could One Day Replace Animal Testing
Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

image_pdfDownload PDFimage_print

A new “metal-coordinated” drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to results of a study published in the journal Thyroid this month.

Researchers at Rush University Medical Center have been pursuing an improved treatment for the minority of hypothyroid patients who don’t respond well to the standard therapy. Now, their investigations into the way thyroid hormones given in tablets are absorbed and metabolized by the body suggest that a metal-coordinated molecule could prove to be a more effective therapy for all hypothyroid patients, according to Dr. Antonio Bianco. He is a professor of medicine at the University of Chicago who was formerly a researcher and clinician at Rush, where the work detailed in the Thyroid paper was completed.

Disease, environmental toxins, medical treatments such as radiation, and genetics all can cause hypothyroidism. Symptoms include fatigue, weight gain, lack of energy, depression, cold intolerance and muscle aches.

The new drug, poly-zinc-liothyronine (PZL), worked well in laboratory studies, Bianco said. Safety tests in animals and clinical trials in humans must still be conducted, and funding must be obtained to support that work. If all goes well, though, PZL could be offered to patients in only a few years, according to Bianco.

“We know enough about thyroid physiology in rats and humans that we feel confident that this drug is ready for prime time” in terms of working as well in humans as it has in the lab, he said.

About 10 to 15 percent of hypothyroidism patients respond poorly to standard treatment

The standard treatment for hypothyroidism is levothyroxine (L-T4), a synthetic version of the thyroid hormone thyroxine (T4), which in a healthy person is secreted by the thyroid gland. However, about 10 to 15 percent of L-T4-treated patients continue to have symptoms of the condition when treated, including weight gain, fatigue, lethargy, mood fluctuations, and problems with memory.

This medical mystery has led physicians to try combination therapy of L-T4, plus liothyronine (L-T3), the synthetic form of the more active thyroid hormone triiodothyronine (T3). However, when L-T3 is given in conventional tablet form, it’s absorbed very rapidly, causing spikes in serum blood levels that may result in heart palpitations, tightness in the chest, sweating and anxiety.

In the study, researchers successfully treated laboratory rats that had been made hypothyroid with a capsule containing PZL, an pharmaceutical compound that is made of zinc bound to three L-T3 molecules. This metal-coordinated drug is packaged in a capsule specially coated to allow it to travel intact through the stomach to the duodenum (the first part of the small intestine). There, the zinc facilitates the slow release of L-T3 for sustained absorption into the blood stream.

In the study, control hypothyroid rats were treated with similar amounts of L-T3. The results were remarkable. Whereas control animals exhibited a spike of T3 in the blood about four hours after taking the L-T3 pills, PZL-treated rats displayed a progressive rise in blood T3 levels that peaked about ten hours later at lower blood levels. When given during eight days, treatment with PZL normalized signs typically observed in hypothyroid rats, such as high blood levels of (the pituitary hormone that is normally used to monitor therapy for hypothyroidism), slow growth rate and higher cholesterol levels.

Has the ‘Holy Grail’ of hypothyroidism treatment been found?

While investigating why a minority of hypothyroid patients still have symptoms even while adhering to the standard L-T4 therapy, these investigators discovered that, in rat models, a steady supply of L-T3 is necessary to “normalize” functional thyroid levels in the blood, and in such tissue areas as the brain, muscles and liver. That discovery gave new urgency to the hunt for a way to effectively deploy L-T3 over time in patients with hypothyroidism.

“A sustained-release L-T3 has been sort of the Holy Grail” in the field, Bianco said — specifically, one that would perform well in clinical trials. PZL appears to solve that key problem and could be used in combination therapy. Bianco said. “When you take L-T3 alone, it’s immediately absorbed. PZL isn’t.”

With PZL, T3 levels in the blood are “sustained over time with a delayed, but more desirable biological response,” the study reported. As a result, PZL “minimizes post-dose peaks in circulating T3 typically seen with L-T3 administration.” In other words, not only is PZL effective, but it also is less of a shock to the body.

Dr. Elizabeth McAninch, an assistant professor in the Rush Division of Endocrinology and Metabolism and researcher in hypothyroidism, who was not involved in this study, says, “This is very exciting from the clinical perspective, because it’s different from any other formulation of LT3 currently available. This is a long-acting form of L-T3, the previous clinical trials have only utilized short-acting L-T3.”

“If [PZL] is deemed to be safe and ready for clinical trial in humans, such trials can help determine if combination therapy can improve the signs and symptoms of hypothyroidism.”

PZL was developed by Synthonics Inc., a Blacksburg, Virginia-based company specializing in metal-coordinated pharmaceuticals. Dr. Scott Palmer, an assistant professor in Rush’s Department of Internal Medicine, is a director and chairman of the scientific advisory board for Synthonics Inc., and a named inventor of the metal-coordinated process.

About author

Related Articles